CBD deep-dive (Switzerland)

CBD in Switzerland: Europe's clearest regulatory framework

Switzerland has an unusually clear regulation for CBD, which distinguishes it from most of its neighbouring countries: cannabis products with less than 1% total THC do not fall under the Narcotics Act. By comparison, the threshold in the EU is 0.2 or 0.3% depending on the country. This is why CBD flowers are legally available in retail here, whereas the same goods would be legally problematic in Germany or France.

However, this clarity has a downside that many overlook: the limit refers to total THC. The decisive factor is always the total THC, i.e. THC plus THCA multiplied by the factor 0.877. A product with 0.4% delta-9-THC and 0.9% THCA has a total THC content of around 1.19% and is therefore classified as a narcotic — even if the packaging says «under 1%». Anyone buying products should therefore insist on a certificate of analysis that shows both values — delta-9-THC alone is not a sufficient indication.

The distinction by product category is also important. Flowers for smoking are regulated as tobacco substitute products and are subject to tobacco tax. Oils for oral ingestion fall under food or medicinal product law, whereby the BLV considers CBD extracts in food to be non-authorized novel foods. Cosmetics containing CBD are subject to the Cosmetics Ordinance. The same substance, three different sets of regulations.

• Switzerland threshold: 1% total THC — EU 0.2–0.3% depending on the country
• Flowers: tobacco substitute, subject to tax, declaration requirement
• Oils: novel food issues, therapeutic claims are inadmissible
• Cosmetics: Cosmetics Ordinance, no efficacy claims without proof

What CBD can do, what it cannot, and how to recognize quality

CBD is non-intoxicating and barely activates the CB1 receptor. It acts indirectly — among other things, by inhibiting the degradation of the body's own endocannabinoids as well as via serotonin and TRPV1 receptors. The most robust evidence exists for a pharmaceutically approved CBD preparation for certain forms of epilepsy. For the applications commonly found in retail — sleep, stress, muscular complaints — the data situation is heterogeneous: there are indications, but no evidence that would justify sweeping therapeutic claims. Such claims are also legally impermissible in Switzerland for non-approved products.

In practice, when it comes to product quality, almost everything depends on the certificate of analysis. It must bear the batch number of the purchased package, be less than twelve months old, state the total THC and, in the case of extracts, also cover pesticides, heavy metals and residual solvents. For oils, the specification in milligrams of CBD per milliliter is also relevant — a percentage figure alone does not allow for a price comparison.

The honest comparative value is always the price per milligram of CBD, not per bottle or per gram of flower.

Navigation through the CBD cluster

The subpages cover effects and the state of research, the various dosage forms, dosage, side effects and interactions, quality testing, and the comparison between full-spectrum, broad-spectrum and isolate.

Those trying CBD for the first time start with dosage and dosage forms; those who already have experience and are making targeted purchases, with quality testing and spectrum comparison. Regarding drug interactions, the following applies: this is a question for your doctor or pharmacist, especially in the case of blood thinners and medications with a narrow therapeutic window.

CBD in Swiss road traffic and the zero-tolerance policy

Anyone who consumes CBD products in Switzerland and subsequently gets behind the wheel often underestimates the legal risk. In Swiss road traffic, a strict zero-tolerance policy applies regarding tetrahydrocannabinol. The legal limit for driving incapacity is set at a detection limit of just 1.5 micrograms of THC per litre of blood. Since even legal CBD products are allowed to contain a small proportion of total THC of up to one percent, this extremely low value in the blood can quickly be exceeded. A positive rapid test by the police inevitably leads to a blood sample being taken and, in the worst-case scenario, to the permanent revocation of the driver's licence.

The distinction between legal CBD consumption and illegal THC consumption is secondary for the authorities during a traffic check, as the pure concentration in the blood determines driving incapacity. Even full-spectrum oils or CBD flowers can lead to an accumulation of THC in the body with regular use. Consumers should be aware that the legislator makes no exceptions here. Anyone wishing to play it safe should completely avoid products containing THC before participating in road traffic or rely exclusively on certified isolates that are demonstrably completely free of any traces of THC.

• Strict limit of 1.5 micrograms of THC per litre of blood in Swiss road traffic.
• Risk of THC accumulation in the body even with regular consumption of legal CBD with less than one percent THC.
• Police rapid tests do not initially distinguish between legal CBD and illegal cannabis.
• Withdrawal of the driving licence and high procedural costs are a risk if the limit is exceeded.

The grey area of CBD foodstuffs and novel food regulations

The Swiss market for CBD products is characterised by a regulatory peculiarity in product declaration. The Federal Food Safety and Veterinary Office (BLV) as well as the Federal Office of Public Health (BAG) classify CBD extracts in foodstuffs as so-called novel foods (Novel Food). Since there is currently no comprehensive European or Swiss authorisation for these extracts, the official sale of CBD-containing foodstuffs, chewing gums or beverages is severely restricted. This leads to many manufacturers declaring their products as cosmetics, raw materials or scented oils to evade the strict requirements of the Foodstuffs Act.

For Swiss consumers, this practice creates considerable intransparency when shopping. Products that are actually intended for oral ingestion carry warning notices such as «Not suitable for consumption» or are sold as pure aroma oils. This not only makes it difficult to assess the actual quality, but also limits the obligation to provide dosage recommendations. Particular caution is therefore advised when purchasing such products, as manufacturers are often not allowed to provide clear instructions for use due to the legal grey area, and the responsibility for correct application is transferred entirely to the consumers.

• Classification of CBD extracts in foodstuffs as Novel Food by the BLV and the BAG.
• Declaration of oral CBD oils as cosmetics or aroma oils to bypass the strict Foodstuffs Ordinance.
• Lack of official dosage and consumption recommendations on packaging due to legal requirements.
• Increased personal responsibility for consumers when selecting and using foodstuffs that are not officially authorised.

Cantonal differences in enforcement and official controls

Although the Swiss Narcotics Act prescribes a nationwide uniform limit of less than one percent total THC, practical enforcement differs significantly between the individual cantons. Cantonal laboratories and police authorities set their own priorities when monitoring points of sale and consumers. While the possession of CBD flowers in public spaces is handled pragmatically in some cantons, other cantons regularly conduct strict random checks. This particularly concerns verifying whether the flowers carried are actually legal CBD or illegal narcotics, which is often difficult to distinguish on site.

During police checks, products are therefore repeatedly seized provisionally. Only a laboratory analysis provides certainty as to whether the limit of one percent has been complied with. If the product exceeds this limit, criminal proceedings may follow. For adults, possession of more than ten grams of illegal THC cannabis for consumption is subject to a fixed penalty fine of one hundred Swiss francs, although here too the cantons set different priorities for enforcement. In case of uncertainty or suspicion of contamination and overdoses, the emergency number of Tox Info Suisse (145) offers an important first point of contact for those affected.

• Federalist enforcement leads to different handling of checks in the Swiss cantons.
• Provisional seizure of CBD flowers during police checks until the exact determination of the total THC content.
• Fixed penalty fine of one hundred Swiss francs if the limit is exceeded, starting from ten grams of THC cannabis.
• Tox Info Suisse as a telephone point of contact in case of health doubts or overdoses.

Distinction from medical cannabis and the Swiss pilot trials

A common misconception concerns the distinction between over-the-counter CBD and medical cannabis in Switzerland. Since the amendment of the law in August 2022, medical cannabis can be prescribed directly by doctors without prior exceptional authorisation from the Federal Office of Public Health. These medical preparations are subject to the strictest quality controls under the Therapeutic Products Act and often have a high THC content that is far above the legal one percent limit for the recreational market. They serve the therapy of severe or chronic illnesses, while over-the-counter CBD is marketed as a wellness product without medical indication.

In parallel, scientific pilot trials under Article 8b of the Narcotics Act are running in various Swiss cities, such as Züri Can or Weed Care in Basel. These time-limited studies investigate the regulated sale of THC-rich cannabis for recreational use under state supervision. They must be strictly separated from the freely accessible CBD market, as participation in these projects is bound to fixed criteria and registration. Anyone who consumes THC cannabis outside of these studies is still operating in the illegal sphere, provided that the total THC content of the product exceeds the legal limit of one percent.

• Medical cannabis has been accessible directly via medical prescription without an FOPH exceptional authorisation since August 2022.
• Strict separation between medical preparations under Swissmedic supervision and over-the-counter CBD products.
• Time-limited pilot trials in Swiss cities are researching the regulated sale of THC cannabis for recreational use.
• Participation in pilot projects requires official registration and is bound to strict scientific requirements.

FAQ